Alpha Profiles · Company Profile

Kairos Pharma, LTD.

Canonical company identity and public leadership record.

https://registry.alpha.ac/companies/kairos-pharma-ltd

Entity: Public listing published
Primary listing: NYSE: KAPA
Verification: Partially verified
Last reviewed: 2026-10-24T04:47:23.804732+00:00

Overview

Alpha's canonical identity and public leadership record for Kairos Pharma, LTD..

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

4 public records

Doug Samuelson

Chief Financial Officer

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: KAPA 10-K executive officersMar 31, 2026

John S. Yu, M.D.

Chief Executive Officer and Chairman of the Board

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: KAPA 10-K executive officersMar 31, 2026

Neil Bhowmick, Ph.D.

Chief Scientific Officer

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: KAPA 10-K executive officersMar 31, 2026

Ramachandran Murali, Ph.D.

Vice President of Research and Development

State: confirmed
Effective: From Mar 31, 2026
Confidence: 94%
Evidence: KAPA 10-K executive officersMar 31, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 24, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.